Allergan has obtained the US Food and Drug Administration (FDA) approval for its XEN Glaucoma Treatment System.

The system is indicated for the management of refractory glaucomas, where previous surgical treatment has failed or in patients with primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are not responsive to maximum tolerated medical therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Implanted through an ab interno approach, the Xen reduces IOP by creating a new drainage channel with a permanent implant that becomes flexible.

"Studies have shown that at 12 months using XEN, patients used, on average, less IOP lowering drops than they did before XEN was implanted."

The XEN Glaucoma Treatment System consists of XEN45 Gel Stent and the XEN Injector, are designed to reduce intraocular pressure (IOP) in patients.

The XEN Gel Stent is made of a gelatin derived from porcine dermis which is then formed into a tube, and then cross-linked with glutaraldehyde.

See Also:

When hydrated, the gelatin expands and becomes flexible which supports the retention of the Gel Stent in its intended location after surgical implantation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The XEN Injector is a single use mechanical delivery system for the preloaded XEN Gel Stent enabling the surgeon to advance and deliver the Gel Stent to the desired location.

University of California professor of Ophthalmology Robert Weinreb said: "XEN is a new option that provides an opportunity for surgical intervention in refractory glaucoma patients.

"XEN can effectively lower IOP, in fact, studies have shown that at 12 months using XEN, patients used, on average, less IOP lowering drops than they did before XEN was implanted."

The treatment system has demonstrated efficacy in reducing IOP in refractory glaucoma patients during the US pivotal trial.